Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Sanford C. Bernstein

Genmab A/S (NASDAQ:GMAB - Get Free Report) was downgraded by equities researchers at Sanford C. Bernstein from a "market perform" rating to an "underperform" rating in a research report issued on Tuesday, Marketbeat Ratings reports.

GMAB has been the subject of a number of other research reports. HC Wainwright reiterated a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Truist Financial cut their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Finally, William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $41.33.

Genmab A/S Stock Up 2.2 %

Shares of NASDAQ:GMAB traded up $0.42 during midday trading on Tuesday, reaching $19.24. The company had a trading volume of 1,715,372 shares, compared to its average volume of 973,396. Genmab A/S has a 1-year low of $18.48 and a 1-year high of $30.50. The stock has a market cap of $12.73 billion, a PE ratio of 11.06, a P/E/G ratio of 2.65 and a beta of 0.98. The business's 50 day moving average price is $20.76 and its 200 day moving average price is $21.71.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marotta Asset Management lifted its holdings in shares of Genmab A/S by 5.8% during the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after buying an additional 739 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in Genmab A/S by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after purchasing an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC grew its position in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after purchasing an additional 950 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.